{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:53:56Z","timestamp":1771030436391,"version":"3.50.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.581189","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T06:35:26Z","timestamp":1603348526000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Outcomes With First-Line PD-1\/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort"],"prefix":"10.3389","volume":"10","author":[{"given":"Pedro","family":"Barata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Whitley","family":"Hatton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arpita","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vadim","family":"Koshkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Manogue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Cotogno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm","family":"Light","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jodi","family":"Layton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnab","family":"Basu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Kilari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Emamekhoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet A.","family":"Bilen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/j.clgc.2016.12.005","article-title":"Real-world survival outcomes and prognostic factors among patients receiving first targeted therapy for advanced renal cell carcinoma: a SEER\u2013medicare database analysis","volume":"15","author":"Pal","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1200\/JCO.2018.36.15_suppl.4500","article-title":"Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): results from cohort A of KEYNOTE-427","volume":"36","author":"McDermott","year":"2018","journal-title":"Am Soc Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1200\/JCO.2019.37.15_suppl.4569","article-title":"KEYNOTE-427 cohort B: first-line pembrolizumab (pembro) monotherapy for advanced non\u2013clear cell renal cell carcinoma (NCC-RCC)","volume":"37","author":"Lee","year":"2019","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"5006","DOI":"10.1200\/JCO.2020.38.15_suppl.5006","article-title":"Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-na\u00efve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260)","volume":"38","author":"Atkins","year":"2020","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1200\/JCO.2020.38.15_suppl.5005","article-title":"Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): a response-based phase II study (OMNIVORE)","volume":"38","author":"McKay","year":"2020","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40425-018-0319-9","article-title":"Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma","volume":"6","author":"Koshkin","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.1200\/JCO.2019.37.15","article-title":"CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate\/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"12028","DOI":"10.1200\/JCO.2020.38.15_suppl.12028","article-title":"Impact of performance status on response and survival among patients receiving checkpoint inhibitors for advanced solid tumors","volume":"38","author":"Krishnan","year":"2020","journal-title":"Am Soc Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/cncr.23769","article-title":"Brain metastasis from renal cell carcinoma","volume":"113","author":"Shuch","year":"2008","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3322\/caac.21411","article-title":"Treatment of renal cell carcinoma. Current status and future directions","volume":"67","author":"Barata","year":"2017","journal-title":"CA Cancer J Clin."},{"key":"B18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.19.01882","article-title":"Results of a multicenter phase ii study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and\/or sarcomatoid features","volume":"38","author":"McGregor","year":"2020","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/CJI.0000000000000270","article-title":"Superimposed clostridium difficile Infection during checkpoint Inhibitor immunotherapy-induced colitis","volume":"42","author":"Babacan","year":"2019","journal-title":"J Immunother"},{"key":"B20","doi-asserted-by":"publisher","first-page":"mdy424","DOI":"10.1093\/annonc\/mdy424.037","article-title":"LBA31 Molecular correlates differentiate response to atezolizumab (atezo)+ bevacizumab (bev) vs sunitinib (sun): results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)","volume":"29","author":"Rini","year":"2018","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1200\/JCO.2019.37.15_suppl.101","article-title":"Biomarker analyses from JAVELIN Renal 101: avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)","volume":"37","author":"Choueiri","year":"2019","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.1200\/JCO.2020.38.15_suppl.5024","article-title":"Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427","volume":"38","author":"McDermott","year":"2020","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.11.001","article-title":"Outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy after immuno-oncology checkpoint inhibitors","author":"Graham","year":"2019","journal-title":"Eur Urol Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41416-018-0104-z","article-title":"The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma","volume":"119","author":"Barata","year":"2018","journal-title":"Br J Cancer."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(19)30513-3","article-title":"Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study","volume":"20","author":"Ornstein","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.581189\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T06:35:28Z","timestamp":1603348528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.581189\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":25,"alternative-id":["10.3389\/fonc.2020.581189"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.581189","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"article-number":"581189"}}